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Cancer patients and their caregivers in 
the face of opioid analgesic treatment 
— opportunities and threats to the 
treatment process
ABSTRACT
Failure to alleviate cancer pain may deteriorate mental functioning, increase depression symptoms, result in the 
clinical diagnosis of demoralization syndrome nonadherence of treatment, functioning discipline, which together, 
may precipitate desire for euthanasia. Increased incidence of pain in patients with advanced or terminal disease 
has been reported to range from 39% to 66.4% depending on the stage of the cancer being experienced. Further, 
the progressive aging of societies and increased life expectancy in cancer patients has changed the dynamics of 
modern treatment processes. Despite their efficacy, the use of opioids as an analgesic treatment during terminal 
disease has been affected by the quality, availability, and negative reputation of these scheduled drugs. This review 
aims to describe the specific factors and limitations of opioid pain management from the perspective of patients 
and their caregivers. Further, we aim to identify and discuss the key factors which determine the success or failure of 
opioid use for the treatment of pain with links to internationally recognized recommendations and current research.
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Introduction
In 2007, a comprehensive review of pain prevalence 
research concluded that, despite clear recommendations 
from the World Health Organization (WHO), pain in 
cancer is still a problem for a large group of patients 
[1]. The International Association for the Study of Pain 
(IASP) declared the year between October 2008 and 
October 2009 as the year for the Global Fight Against 
Cancer Pain [2]. During this period, the IASP intro-
duced many initiatives for both the medical community 
and the general public to raise awareness of cancer pain 
and to provide useful information in its management. 
Pain relief is considered a human right. In 2013, the 
United Nations stated that the lack of effective treat-
ment to assist those dealing with pain is a violation of the 
prohibition against torture and inhuman or degrading 
treatment [3]. Since the WHO announced the principles 
of the analgesic ladder in 1986, recommendations for 
the treatment of cancer pain have been increasingly 
published, both by recognized international and national 
organizations [4].
Global opioid use increased from 28 mg in 2005 to 
42 mg morphine equivalents per capita in 2012 [5]. Ad-
ditionally, opioid drug availability increased in 67 coun-
tries between 2006 and 2010 (ACM index increase) [5]. 
The understanding of the mechanisms of cancer pain, 
methods of pain assessment and treatment, and the 
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number of publications on this topic have all increased 
significantly. Despite these successes, pain is still the 
most common and one of the most severe symptoms 
accompanying disease and cancer treatment. According 
to a 2016 review [6] (4117 studies from 2005–2014), the 
prevalence of pain in patients with advanced or terminal 
disease was 66.4% (vs. 64% in 2007) [7], 55% (vs. 59% 
in 2007) during cancer treatment, and 39.3% (vs. 33% in 2007) 
in post-treatment patients. 
From the perspective of patients and 
caregivers
Over the years, the ability to assess the effectiveness 
of pain relief strategies has been hampered by differ-
ences in the methods used to estimate pain prevalence 
[8] as well as differences in the index of adequacy of 
opioid consumption [9] (different lists of opioid drugs 
included in comparisons between countries [10]). These 
differences are often misleading or fail to explain the 
discrepancy between medical advances, increased 
availability of treatment, and the lack of expected im-
provement in the pain management caused by both the 
disease and its treatment.
The ability to globally assess the quality and avail-
ability of opioid analgesic cancer treatments is further 
undermined by the co-occurrence of extreme anti-opioid 
psychology in recent years — opioidophobia [11]. The 
problems of quality and availability have been highlight-
ed in Poland [12] and the United States, respectively 
[13, 14]. While there is limited access to opioids in most 
countries, the misuse of controlled drugs is a major 
public health problem in some countries.
By 2030, it is estimated that 21.4 million new cases 
of cancer are expected worldwide [15]. Thus, for both 
clinical practice and research, the identification and 
understanding the conditions that determine effective 
pain therapy and investigating the other variables that 
model the treatment processes of specific patients are 
still urgently required. 
The role of patients in pain management failure 
was recognized and identified as a significant factor in 
the 1994 Agency for Healthcare Research and Quality 
(AHCPR) recommendations [16]. In those recommen-
dations, the AHCPR identified patient-specific barriers 
to the treatment of pain such as a resistance to commu-
nicate the severity of the pain being experienced due to 
fear of the side effects of the treatment, disbelief in its 
efficacy, fear of undermining the anti-cancer treatment, 
or a misunderstanding of the link between pain and 
disease progression due to incorrect information [17]. In 
recent decades, the contribution of both the patient and 
family attitudes to pain-treatment-failure has changed 
with social and cultural developments and needs to be 
continuously monitored like other treatment success 
factors [18–20].
Quality of life as determined by health 
The progressive aging of the human population 
in combination with the lengthening of survival periods in 
cancer patients are changing the dynamics of medical 
interventions. These have led to a shift from a “society 
at risk” in which disease was treated as a transitional 
state between lost and regained health to a “remis-
sion society” [21], in which prolonged and multistep 
treatment makes it possible to live with a chronically 
life-threatening disease at the expense of accepting the 
impact and regime of treatment. Chronic treatment 
requires the rebuilding of a lifestyle that may have been 
broken down by the diagnosis and is based on the values 
and relationships necessary to maintain it [22]. This new 
lifestyle requires perseverance to adapt to the limitations 
and recommendations of the primary healthcare persons 
and caregivers in the case of multimorbidity, coping skills 
in dealing with the health care system but also forces 
one to relate the proposed lines of treatment (including 
pain management) to all valued dimensions of life, not 
only somatic but also functional or psychosocial [23]. 
Additionally, it has been shown that patients may 
experience several deleterious health conditions due 
to a failure to manage pain and other debilitating so-
matic symptoms. These can include a deterioration in 
psychological functioning, exacerbating symptoms of 
depression [24], or clinical demoralization syndrome 
(in the ICD-10 International Classification of Diseases, 
category R45.3 Demoralization, and apathy) [25]. These 
by-products of ineffective pain management make it 
seem impossible for some patients to live with the rigors 
of treatment and can lead to the risk of desiring eutha-
nasia [26]. Further, the feelings of hopelessness, help-
lessness, and a loss of purpose that are associated with 
demoralization symptoms can reduce compliance with 
longer-term treatment [27]. However, studies investigat-
ing this phenomenon have highlighted the importance of 
the patients’ maintenance of social relationships, a sense 
of being recognized in their subjective role as well as 
their relationship with the doctor as important factors 
which help with successfully combating demoralization. 
Knowledge and attitudes can shape 
expectations 
The results of Garzón’s 2018 study [28] support the 
hypothesis that demoralization is related to a poor-quality 
relationship with the treatment team. Additionally, Rob-
inson et al. [29] highlighted the impact of patient-centered 
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communication on reducing feelings of hopelessness and 
increasing satisfaction with care. Their data points to the 
non-informational aspects of communication — such as 
feeling in control of one’s treatment, being involved in 
the decisions made about it, being seen as a person, and 
being able to personally contact the doctor when there 
are concerns or questions.
Patients’ attitudes and expectations about participat-
ing in long-term (months to years) cancer treatment 
process are shaped by stereotypes, publicly available in-
formation, and the knowledge they gain from physicians 
and other treatment team members during treatment. 
A 2017 study by Jarosz et al. [30] indicated that the 
singular strategy of informing patients about the nature 
of opioid treatment without any other information or 
support is insufficient. Their data indicated that patients 
exhibited the least knowledge about opioids among the 
groups studied: doctors, nurses, students, and even lower 
than the general population. 
In a study by Graczyk et al. (2017) [31], the negative 
effect of medical consultations on opioid aversion was as-
sessed. In that study, the authors found that the triggering 
or reinforcing of a patient’s fear of opioid analgesic treat-
ment occurred when patients interacted with physicians 
whose own fears about the use of opioids influenced their 
clinical practice. Undoubtedly, the process of informing 
patients about treatment options includes – in addition 
to information about the disease and its treatment — an 
insight into the attitude of the physician which may 
reinforce or weaken a patients’ defense mechanisms, at-
titudes, and expectations. Further, when an insufficient 
amount of time is taken by the physician to clearly explain 
both the disease and treatment regimens, the patient 
may go into a state of denial which makes their further 
cooperation in the treatment process difficult.
Early implementation of symptomatic 
treatment — an opportunity for 
compliance
Growing evidence suggests that the survival time for 
cancer patients is also dependent on the efficient control 
of disease symptoms [32]. Further, an increasing number 
of studies have shown that effective pain management 
contributes significantly to an improved quality of life [32]. 
Pain management therapy is already defined as an 
essential part of cancer treatment [32]. “Supportive 
care” [33] has become a part of the European Society for 
Medical Oncology’s (ESMO) 2018 proposed concept of 
“patient-centered care” [34] to include both supportive 
and palliative treatment. Moreover, studies have shown 
that the term “palliative” can have negative connota-
tions for doctors, patients, and their caregivers and can 
cause significant delays in the referral of symptomatic 
or interventional treatments, including those related to 
pain management [35]. The same document emphasizes 
the need for the provision of care from the moment of 
cancer diagnosis and its delivery in a way that tracks 
changes in patients’ needs and conducts a holistic as-
sessment of the level of satisfaction of those needs — at 
the time of each consultation.
Also, in the 2016 recommendations, ASCO points 
to the need to integrate treatment and palliative care, 
which should involve, in addition to treating symptoms, 
including pain, the building of relationships with patients 
and their caregivers, educating both parties about the 
disease and its prognosis, setting treatment goals and 
supporting treatment decisions [36]. 
From the moment the diagnosis is communicated 
throughout the entire treatment process, there is 
room for building a therapeutic alliance between the 
physician/treatment team and the patient, leading to 
increased adherence to pain management recommen-
dations, as well as concordance in making treatment 
choices and shared responsibility for making and carry-
ing out decisions (self-management) [37, 38].
Patient and caregiver interactions 
shaping knowledge and attitudes
The National Institute for Health and Care Excel-
lence (NICE) recommendations for the treatment of 
pain with opioid medications point first to the need 
for a conversation that includes elements of patient 
and caregiver education. Even before prescribing opi-
oid medications, a physician-patient discussion about 
treatment concerns is recommended. These discussions 
should include a clarification of beliefs and concerns 
about potential addiction, tolerance, side effects, and 
disease progression that may be induced when using 
strong opioids. As a second step, an introduction of both 
verbal and written information regarding cancer treat-
ment is recommended, including when and why they are 
used, their expected effectiveness, possible side effects, 
signs of toxicity, and other notable information [39]. 
An important element of education (both in countries 
with opioidophobia and those experiencing an opioid 
epidemic) is the consistency of information provided to 
patients at all stages of treatment: from family physicians 
[40, 41] to oncologists, to specialists in palliative medi-
cine [42], pain management or pharmacists, whose role 
is not only to assess whether a prescription for opioid 
analgesics is correctly issued [43].
A poor response to pain management may be due to 
cognitive, psychological, social, cultural factors, or any 
combination of all four [this fact is addressed in Standard 
4 of the European Federation for the Treatment of Pain 
in Cancer (EFIC) 2019 pain management standards] [44]. 
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In each of these cases, low adherence or a complete 
lack of adherence disrupts the course of therapy and 
limits or nullifies, the treatment regimen’s effective-
ness [45]. 
The degree of compliance to therapeutic guidelines 
for opioid use is estimated in some analyses to be around 
51–70%, however, in some studies, it is as high as 90% [46]. 
The high adherence is attributed to high levels of patient 
motivation and patient knowledge which is derived 
from the frequency and quality of the interactions with 
the interdisciplinary team during treatment during the 
onset of side-effects (such as constipation or nausea). 
Further, in that study, 8 of 198 patients exceeded the 
recommended doses by a small amount. This increase 
in dose was attributed to an enhanced tolerance to 
the medications the patients were taking. The lack of 
negative effects on patient cooperation in treatment, 
regardless of patient-specific belief barriers, is explained 
by adequate, early education and additional supportive 
treatment during cancer therapy. 
Barriers to pain management due to 
knowledge and attitudes 
A review of studies from 1986 to 2007 which tracked 
the relationship between barriers based on patients’ 
cognitive rationale [knowledge, beliefs, attitudes as 
measured by Barriers Questionnaire (BQ)] [47] and 
the adequacy of the treatment regimen used for pain 
[Pain Management Index (PMI)] [48] showed that pa-
tients with a negative PMI, which defines a suboptimal 
use of analgesics, had a significantly higher BQ score 
than those who were treated adequately. Additionally, 
patients who were reluctant to tell their physician about 
their pain and were reluctant to take pain medica-
tion presented higher levels of cognitive barriers than 
those who did not exhibit hesitancy [49]. Deandrea et 
al. (2008) [50] retrospectively analyzed several stud-
ies from 1987 to 2007 which used PMI (26 papers) as 
a measure for the effectiveness of pain management 
treatments. Their data indicated that 43% of patients 
are treated with inadequate regimens (PMI defined as 
“an index that subtracts the patient’s rating of pain from 
the rating of the strongest analgesic agent”).
The inadequacy or ineffectiveness of adequate 
treatment can be influenced both intentionally or 
unintentionally by patients [51]. These patient-driven 
factors include whether patients report the pain they 
are experiencing, how adequately they describe the 
pain, whether they talk about their concerns, doubts 
about medication dosing, and finally, how they follow 
the recommendations in the long term (self-reported 
skipping of doses at lower pain sensations, increasing 
at higher ones). 
A lack of current knowledge, false beliefs, and 
negative attitudes about opioid analgesic treatment are 
identified in many studies as common obstacles among 
patients, caregivers, and physicians. The most commonly 
shared beliefs in these groups are the fear of addiction, 
the development of tolerance, and the onset of unpleas-
ant side effects during opioid use [52]. 
Specific concerns for patients are:
 — concerns about distracting the physician’s focus on 
the cancer treatment, 
 — concerns about receiving the reputation as being 
a difficult or complaining patient,
 — the belief that pain is both an important informative 
indicator on the course of the disease as well as being 
necessary for its treatment,
 — fatalistic attitude to the possibility of pain relief. 
Beliefs shared by patients and caregivers affecting 
attitudes toward opioid analgesic treatment:
 — opioids are used only in the last days of illness,
 — they cause cognitive impairment or limitation (or 
even euthanasia) 
 — their use will be met with a negative reaction from 
the family when informed that they are taking nar-
cotic drugs. 
In addition, beliefs that are based on social stereo-
types and religious beliefs, such as the value placed 
on experiencing suffering, are less well verbalized and 
difficult to disclose and research [53–58].
Opportunities for more appropriate 
use of opioid analgesic treatment 
due to knowledge and attitudes 
— communication and education
The positive evolution of the knowledge on the 
use of opioid analgesic treatment and its proper com-
prehension is possible if patients and caregivers are 
provided with useful, understandable, and current 
information. Educational programs and recommenda-
tions are dedicated to establishing and developing this 
educational change. 
Interventions aimed at educating patients about 
pain management regimens in cancer have already 
been analyzed in systematic reviews [59], which high-
lighted the following key factors for patients: informa-
tion about the nature and mechanisms of pain as well 
as advice on how to communicate and describe the 
pain. For clinicians, the key factors include: how to 
enhance pain assessment during consultations, how 
to deal with barriers to adherence, how to maintain 
regularity of pain assessment. These and other fac-
tors were described as elements of a multi-stage and 
staggered educational process. The pie chart in the 
middle indicates the process necessary for optimal 
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•Patient mis-interprets pain 
  or accepts pain as inevitable.
•Patient is uncertain how to seek 
  medical attention.
•Patient falls to report pain
• Patient/IICP communication 
   about pain is suboptimal 
• Pain assessment is suboptimal 
• IICP fails to prescribe adequate analgesic regimen 
• Intentional non-adherenee by patient 
   (e.g. decision not to mask pain, fear 
   of side effects or addiction) 
• Unintentional nonadherence by patient 
   — misunderstanding of dosing regimen, 
   forgetfulness. 
• IICP fails to consider adjuvant anticancer 
   therapies, or non-pharmacological therapies 
• Pain changes e.g. due to disease 
   progression/analgesic tolerance. 
   Pain is not re-assessed
Figure 1. Essential steps for optimal cancer pain management [by: Adam R, Bond C, Murchie P. Educational interventions for 
cancer pain. A systematic review of systematic reviews with nested narrative review of randomized controlled trials. Patient 
Educ Couns. 2015]
treatment of cancer pain. External frames illustrate 
the barriers that can hinder the effective treatment of 
cancer pain. Educational interventions have usually 
dealt with one or more of these identified barriers 
(Fig. 1) [59].
Influencing the beliefs and attitudes of patients 
and their caregivers requires trust between the person 
providing the information and its source [60]. It is im-
portant to create and encourage an actively sustained 
patient-centered line of communication that relates 
to the patient’s values and goals. In their search for 
principles of optimal patient and caregiver education, 
Luckett et al. (2019) [61] based on a systematic review 
(353 publications) and meta-analysis of 15 studies, 
singled out interventions that focused on enhancing 
patients’ sense of self-efficacy as particularly effec-
tive. The authors emphasized that not only imparting 
knowledge but also learning new skills is crucial in pain 
management [61].
Summary
Ensuring that patients with pain have access [62] to 
analgesic treatment, including those which are based 
on opioid medication, is important. However, preparing 
patients to participate in the treatment process which 
will enable them to live with their disease to the highest 
possible quality whilst counteracting the adverse health 
effects of the substances themselves, are two sides of 
a single issue of the use of drugs based on controlled 
substances that still need to be urgently improved upon. 
Here, the studies reviewed have highlighted opioid 
dosage as an important factor for the inadequate pain 
management of patients with oncologic diseases. Both 
the inadequately low or high use of narcotic medications 
may be the result of an inconsistent and inadequately 
supported education process in the knowledge and 
skills of the medical community, patients, and their 
caregivers at various stages of treatment. Novel research 
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10. Bennett M.I. et al., 2019 [72] 
In English
which elucidates knowledge and interrogates attitudes 
towards opioid analgesic regimens and regularly inves-
tigates the effects of disruptors (such as fashion, social 
trends, etc.) on this education can contribute to the 
early detection of adverse or harmful trends. However, 
this knowledge will not, by itself, change the attitudes 
and motivation of physicians and other members of 
treatment teams to use the available current knowl-
edge, apply it in clinical practice, and communicate it 
to patients and caregivers. This task remains in physi-
cians’ hands, as does improving and applying knowl-
edge of the processes that patients living with chronic 
life-shortening illnesses undergo. 
The studies and recommendations described here 
indicate that with the development of ever more modern 
treatment lines, which determines the success or failure 
of physicians’ work, the ability to keep a patient on sev-
eral years or decades of treatment is enhanced. Further, 
the ability to build, correct, and maintain collaborative 
relationships with treated patients and their caregivers 
remains an essential aspect of palliative care.
The treatment of pain with controlled substances 
such as opioids requires a special approach and open-
ness with patients. Since these drugs are often feared by 
patients and their relatives, and often even by medical 
personnel themselves; their use must be accompanied 
by a conviction that the prescription of opioids is ap-
propriate. Additionally, patients should be informed 
from the beginning of treatment about the purpose, 
form, and limitations of pain therapy and, importantly, 
have a say in the therapeutic decisions made in this 
regard. As discussed in this review, the effectiveness 
of pain treatment is highly dependent on the level of 
patients’ cooperation, which in turn, is derived from 
their knowledge, expectations, and beliefs about the 
therapy applied. Alternatively, inadequate knowledge 
among physicians and other medical personnel can 
lead to inadequate treatment regimens and doubts 
about the right course of action among patients and 
their loved ones. Fortunately, the availability of nu-
merous guidelines and recommendations in this area 
makes it possible to reach for reliable, transparent, 
and detailed sources of knowledge, which can not only 
further improve treatment outcomes but also reduce 
both opioidophobia and the opioid epidemic. Selected 
studies in Table 1.
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